The Biological Synthesis and the Function of Mucin 2 in Pseudomyxoma Peritonei

Yu-Lin Lin1, Yan Li1

  • 1Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University (Beijing Technical Training Base of Tumor Deep Hyperthermia and Whole-Body Hyperthermia), Department of Oncology, Capital Medical University, Beijing, 100038, People's Republic of China.

Insights

Pseudomyxoma peritonei (PMP) involves excessive mucus due to MUC2. Understanding MUC2

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Pseudomyxoma peritonei (PMP) is characterized by excessive mucus secretion, leading to severe complications and mortality.
  • Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is standard treatment, but recurrence is common.
  • Mucin 2 (MUC2) is the primary mucin in PMP and is crucial for mucus sclerosis.

Purpose of the Study:

  • To provide a comprehensive review of MUC2 biosynthesis and molecular characteristics.
  • To explore potential mucolytic strategies for PMP treatment.

Main Methods:

  • Systematic review of MUC2 gene structure, transcription, translation, and post-translational modification.
  • Analysis of MUC2 tertiary structure and factors influencing mucus viscoelasticity.

Main Results:

  • MUC2 is a highly glycosylated protein, with glycans comprising 80-90% of its dry weight.
  • MUC2 forms a complex, bead-like filament assembly.
  • Factors like salt concentration, pH, mucin concentration, and trefoil factors influence mucus viscoelasticity.

Conclusions:

  • Understanding MUC2's molecular biology is key to developing novel mucolytic therapies for PMP.
  • Targeting MUC2's properties could lead to future drugs that soften or dissolve PMP-associated mucus.